Apollo Hospitals’ Q1FY25 Results
- 16 Aug 2024
- Apollo Hospitals reported a 3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter ended June (Q1FY25). On a year-on-year (YoY) basis, it witnessed a growth of 15.2%.
- Its expenses for the quarter were up by 2% QoQ and 12.5% YoY.
- The net profit increased 22.1% QoQ and 81.9% YoY.
- The earnings per share (EPS) of Apollo Hospitals stood at 21.2 during Q1FY25.
Apollo Hospitals’ Financial Statements for Q1FY25:
Total income | 4,446 | 4,972 | 5,123 | 3.0% | 15.2% |
Total expenses | 4,182 | 4,612 | 4,704 | 2.0% | 12.5% |
Profit before tax | 270 | 368 | 430 | 16.8% | 59.3% |
Tax | 97 | 110 | 115 | 4.3% | 18.5% |
Profit after tax | 173 | 258 | 316 | 22.1% | 81.9% |
Earnings per share | 11.6 | 17.7 | 21.2 |
Financials:
- Revenue: Increased by 15.2% YoY, rising from ₹4,446 crores in Q1FY24 to ₹5,123 crores in Q1FY25.
- Total Expenses: Rose by 12.5% YoY, from ₹4,182 crores in Q1FY24 to ₹4,704 crores in Q1FY25.
- Profit After Tax: Witnessed an impressive increase of 81.9% YoY, from ₹173 crores in Q1FY24 to ₹316 crores in Q1FY25.
- EBITDA: EBITDA rose 33% YoY to ₹675 crores in Q1FY25.
- Earnings Per Share (EPS): Improved from ₹11.6 in Q1FY24 to ₹21.2 in Q1FY25.
Management Commentary:
Prathap C. Reddy, Chairman of Apollo Hospitals Group, said,
“We continue to lead the industry in adopting and implementing best-in-class healthcare solutions and technologies to push the boundaries of healthcare for better patient outcomes. Our experts have achieved significant milestones, such as performing India's first robotic cytoreductive surgery, introducing the CORI Surgery System for joint replacements, and conducting the first TRIC Valve Procedure in a patient with two prosthetic valves in India.”
He also added, "We are also championing efforts to counter the growing menace of non-communicable diseases (NCDs) in India. This year’s ‘Health of the Nation’ report indicates that India is on the verge of becoming the cancer capital of the world. We are committed to tackling NCDs through an integrated approach driven by our leading experts and supported by technological innovations, aiming to reduce their impact and enhance patient outcomes. In the first quarter of FY25, we have seen significant growth and improved the reach of our retail operations."
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.